Leucid Bio
Leucid Bio develops next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors. The company utilizes a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the natural lateral distribution of signaling domains in immune receptors. Its lead asset, LEU011, is an autologous therapy targeting NKG2D stress ligands which are expressed on a majority of human tumor cells.
Visit websiteLondon, UK
Biotechnology
Oncology
Healthtech
Funding summary
- Total raised
- €13.6M
- Funding rounds
- 1
Investors in Leucid Bio
Investors on record for Leucid Bio. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Leucid Bio?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors